Yonsei Med J.  2019 Mar;60(3):235-242. 10.3349/ymj.2019.60.3.235.

Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon

• Choi YY
• Cho M
• Kwon IG
• Son T
• Kim HI
• Choi SH
• Cheong JH
• Hyung WJ

• KMID: 2441301
• DOI: http://doi.org/10.3349/ymj.2019.60.3.235

Abstract

As radical gastrectomy with lymph node dissection is currently the best strategy to cure gastric cancer, the role of the surgeon remains quite important in conquering it. Dr. Sung Hoon Noh, a surgeon and surgical oncologist specializing in gastric cancer, has treated gastric cancer for 30 years and has conducted over 10000 cases of gastrectomy for gastric cancer. He first adapted an electrocautery device into gastric cancer surgery and has led standardization of surgical procedures, including spleen preserving gastrectomy. His procedures based on patient-oriented insights have become the basis of the concept of enhanced recovery after surgery. He has also contributed to improving patient's survival through adoption of a multidisciplinary approach: he proved the benefit of adjuvant chemotherapy after radical D2 gastrectomy for stage II/III gastric cancer in clinical trials, updating treatment guidelines throughout the world. Dr. Noh also opened the era of precision medicine for treating gastric cancer, as he developed and validated a mRNA expression based algorithm to predict prognosis and response to chemotherapy. This article reviews his contribution and long history of service in the field of gastric cancer. The perspectives of this master surgeon, based on his profound experience and insights, will outline directions for integrative multidisciplinary health care and how can surgeons prepare for the future.

Keyword

Gastric cancer; surgery; precision medicine; chemotherapy; perspective

MeSH Terms

Chemotherapy, Adjuvant
Delivery of Health Care
Drug Therapy
Electrocoagulation
Gastrectomy*
Lymph Node Excision
Precision Medicine
Prognosis
RNA, Messenger
Spleen
Stomach Neoplasms*
Surgeons
RNA, Messenger

Figure

• 

  Fig. 1 Annual number of gastrectomy cases performed by Dr. Noh. STG, subtotal gastrectomy; TG, total gastrectomy including completion total gastrectomy.

• 

  Fig. 2 Changes in overall survival for patients with gastric cancer treated at Yonsei Gastric Cancer Center according to stage (AJCC 7th) and time. AJCC, American Joint Committee on Cancer.

Reference

1. Billroth T. [Offenes schreiben an Herrn Dr. L. Wittelshofer]. Wien Med Wochenschr. 1881; 31:161–165.

2. Choi YY, Cheong JH. Beyond precision surgery: molecularly motivated precision care for gastric cancer. Eur J Surg Oncol. 2017; 43:856–864.

3. Choi YY, Noh SH, Cheong JH. Molecular dimensions of gastric cancer: translational and clinical perspectives. J Pathol Transl Med. 2016; 50:1–9.

4. Kwon IG, Cho I, Guner A, Kim HI, Noh SH, Hyung WJ. Minimally invasive surgery as a treatment option for gastric cancer in the elderly: comparison with open surgery for patients 80 years and older. Surg Endosc. 2015; 29:2321–2330.

5. Kwon IG, Cho I, Choi YY, Hyung WJ, Kim CB, Noh SH. Risk factors for complications during surgical treatment of remnant gastric cancer. Gastric Cancer. 2015; 18:390–396.

6. Kwon IG, Son T, Kim HI, Hyung WJ. Fluorescent lymphography-guided lymphadenectomy during robotic radical gastrectomy for gastric cancer. JAMA Surg. 2018; 11. 14. [Epub]. DOI: 10.1001/jamasurg.2018.4267.

7. Seo WJ, Son T, Roh CK, Cho M, Kim HI, Hyung WJ. Reduced-port totally robotic distal subtotal gastrectomy with lymph node dissection for gastric cancer: a modified technique using Single-Site® and two additional ports. Surg Endosc. 2018; 32:3713–3719.

8. Woo Y, Goldner B, Son T, Song K, Noh SH, Fong Y, et al. Western validation of a novel gastric cancer prognosis prediction model in US gastric cancer patients. J Am Coll Surg. 2018; 226:252–258.

9. Lee JH, Tanaka E, Woo Y, Ali G, Son T, Kim HI, et al. Advanced real-time multi-display educational system (ARMES): an innovative real-time audiovisual mentoring tool for complex robotic surgery. J Surg Oncol. 2017; 116:894–897.

10. Obama K, Kim YM, Kang DR, Son T, Kim HI, Noh SH, et al. Long-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy. Gastric Cancer. 2018; 21:285–295.

11. Choi YY, Bae JM, An JY, Kwon IG, Cho I, Shin HB, et al. Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J Surg Oncol. 2014; 110:129–135.

12. Choi YY, Kim H, Shin SJ, Kim HY, Lee J, Yang HK, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg. 2018; 05. 01. [Epub]. DOI: 10.1097/SLA.0000000000002803.

13. Lee J, Kim H, Lee JE, Shin SJ, Oh S, Kwon G, et al. Selective cytotoxicity of the NAMPT inhibitor FK866 toward gastric cancer cells with markers of the epithelial-mesenchymal transition, due to loss of NAPRT. Gastroenterology. 2018; 155:799–814.

14. Cheong JH, Yang HK, Kim H, Kim WH, Kim YW, Kook MC, et al. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 2018; 19:629–638.

15. Park KC, Kim SW, Jeon JY, Jo AR, Choi HJ, Kim J, et al. Survival of cancer stem-like cells under metabolic stress via CaMK2α-mediated upregulation of sarco/endoplasmic reticulum calcium ATPase expression. Clin Cancer Res. 2018; 24:1677–1690.

16. Roh CK, Choi YY, Choi S, Seo WJ, Cho M, Jang E, et al. Single patient classifier assay, microsatellite instability, and Epstein-Barr virus status predict clinical outcomes in stage II/III gastric cancer: results from CLASSIC trial. Yonsei Med J. 2019; 60:132–139.

17. Choi YY, Jang E, Seo WJ, Son T, Kim HI, Kim H, et al. Modification of the TNM staging system for stage II/III gastric cancer based on a prognostic single patient classifier algorithm. J Gastric Cancer. 2018; 18:142–151.

18. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Okajima K. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg. 1995; 19:532–536.

19. Choi YY, Noh SH, Cheong JH. Evolution of gastric cancer treatment: from the golden age of surgery to an era of precision medicine. Yonsei Med J. 2015; 56:1177–1185.

20. Choi YY, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH. Current practice of gastric cancer treatment. Chin Med J (Engl). 2014; 127:547–553.

21. Oh SJ, Hyung WJ, Li C, Song J, Kang W, Rha SY, et al. The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. J Surg Oncol. 2009; 99:275–280.

22. Lee KY, Noh SH, Hyung WJ, Lee JH, Lah KH, Choi SH, et al. Impact of splenectomy for lymph node dissection on long-term surgical outcome in gastric cancer. Ann Surg Oncol. 2001; 8:402–406.

23. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006; 93:559–563.

24. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017; 265:277–283.

25. Kim YN, Aburahmah M, Hyung WJ, Noh SH. A simple method for tension-free Billroth I anastomosis after gastrectomy for gastric cancer. Transl Gastroenterol Hepatol. 2017; 2:51.

26. An JY, Yoon SH, Pak KH, Heo GU, Oh SJ, Hyung WJ, et al. A novel modification of double stapling technique in Billroth I anastomosis. J Surg Oncol. 2009; 100:518–519.

27. Noh SH, Yoo CH, Chung HC, Roh JK, Shin DW, Min JS. Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. Oncology. 2001; 60:24–30.

28. Jeung HC, Rha SY, Jang WI, Noh SH, Chung HC. Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. Br J Surg. 2002; 89:460–466.

29. Cheong JH, Shen JY, Song CS, Hyung WJ, Shen JG, Choi SH, et al. Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer. Ann Surg Oncol. 2007; 14:61–68.

30. Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y, Matsuda M, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009; 250:242–246.

31. Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016; 20:367–373.

32. Lee JH, Hyung WJ, Noh SH. Comparison of gastric cancer surgery with versus without nasogastric decompression. Yonsei Med J. 2002; 43:451–456.

33. Hyung WJ, Lee JH, Lah KH, Noh SH. Intraoperative needle decompression: a simple alternative to nasogastric decompression. J Surg Oncol. 2001; 77:277–279.

34. Hyung WJ, Song C, Cheong JH, Choi SH, Noh SH. Percutaneous needle decompression during laparoscopic gastric surgery: a simple alternative to nasogastric decompression. Yonsei Med J. 2005; 46:648–651.

35. Kim J, Lee J, Hyung WJ, Cheong JH, Chen J, Choi SH, et al. Gastric cancer surgery without drains: a prospective randomized trial. J Gastrointest Surg. 2004; 8:727–732.

36. Lee J, Choi YY, An JY, Seo SH, Kim DW, Seo YB, et al. Do all patients require prophylactic drainage after gastrectomy for gastric cancer? The experience of a high-volume center. Ann Surg Oncol. 2015; 22:3929–3937.

37. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008; 359:453–462.

38. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010; 11:439–449.

39. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006; 7:309–315.

40. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017; 20:1–19.

41. Cunningham D, Chua YJ. East meets west in the treatment of gastric cancer. N Engl J Med. 2007; 357:1863–1865.

42. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355:11–20.

43. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345:725–730.

44. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379:315–321.

45. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15:1389–1396.

46. Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013; 11:531–546.

47. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24:Suppl 6. vi57–vi63.

48. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003; 349:247–257.

49. Network NCC. Clinical practice guidelines in oncology: colon cancer. 2016. accessed on 2016 March 25. Available at: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.

50. An JY, Kim H, Cheong JH, Hyung WJ, Kim H, Noh SH. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer. 2012; 131:505–511.

51. Kim SY, Choi YY, An JY, Shin HB, Jo A, Choi H, et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: results from a large cohort with subgroup analyses. Int J Cancer. 2015; 137:819–825.

52. Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol. 2017; 3:1197–1203.

53. Choi YY, Cheong JH. To treat, or not to treat, that is the question: biomarker-guided adjuvant chemotherapy for stage II and III gastric cancer. Ann Surg. 2018; 11. 22. [Epub]. DOI: 10.1097/SLA.0000000000003102.

54. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21:1350–1356.

55. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360:790–800.

56. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351:2817–2826.

57. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018; 379:111–121.

58. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513:202–209.

59. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011; 141:476–485.

60. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21:449–456.

61. Gambardella V, Cervantes A. Precision medicine in the adjuvant treatment of gastric cancer. Lancet Oncol. 2018; 19:583–584.

62. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016; 17:309–318.

63. Beom SH, Choi YY, Baek SE, Li SX, Lim JS, Son T, et al. Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. BMC Cancer. 2018; 18:1116.